Morning Brief — Tuesday, September 8, 2026

Market Overview

Markets are opening mixed with SPY down ~0.1% as rising oil prices and Canadian retaliatory tariffs weigh on sentiment heading into a week with key inflation data. The AI infrastructure and memory trade remains the dominant theme, with Goldman flagging breakout signals in memory stocks and Oracle rallying 5% on a Morgan Stanley price target raise. Biotech is carving out a parallel rally leg, with IBB having outperformed the S&P 500 by 22 points over the last three months — and today’s Phase 3 catalyst names suggest that run isn’t done.

Claude’s Call

UP — Despite the mixed futures, the tape is being pulled higher by too many high-quality catalysts (PHVS Phase 3, ROIV Phase 2, IONQ guidance raise, SEI EBITDA raise, Goldman memory breakout call) for the broad market to close red. AI infrastructure and biotech are acting as dual engines, and with oil’s spike contained and no macro data breaking today, the path of least resistance is a modest grind higher driven by sector leadership rather than broad enthusiasm.

Top Movers

PHVS (+21.1%) — $42.67 → $46.29 (+8.5% upside) Thesis: This is the real deal — Pharvaris just printed an 83% reduction in HAE attack rate vs. placebo in the pivotal Phase 3 CHAPTER-3 trial for deucrictibant XR. That’s not a marginal beat; that’s a label-defining number. HAE is an underserved orphan market where once-daily oral therapy over current IV options is a massive QoL win. The stock is trading at the 6-month high and the 20-day high simultaneously — it’s in price discovery mode with no overhead resistance. RBC had already flagged upside potential pre-data, which means institutional positioning was building into this. Levels: Exit at Fib 1.272 extension of $46.29. First support at Fib 23.6% retracement of $37.92; SMA-50 at $34.94 is the real floor if sentiment reverses.

ROIV (+11.2%) — $38.83 → $43.31 (+11.5% upside) Thesis: Mosliciguat just hit a 56.3% reduction in pulmonary vascular resistance in the Phase 2 PHocus study for PH-ILD — a disease space with massive unmet need and limited approved therapies. Critically, Roivant is also commercializing Lisraya (dermatomyositis, $35K/month list price) RIGHT NOW, so this isn’t a binary science bet — it’s a multi-program biotech with a live revenue stream and a fresh pipeline catalyst. The stock is at a 6-month high, tracking an all-time high. This move has fundamental legs, not just momentum. Levels: Exit at Fib 1.272 extension of $43.31. Support at Fib 23.6% of $36.56; SMA-50 at $35.39 is the stop-loss anchor.

SEI (+14.1%) — $62.77 → $65.97 (near-term) → $93.61 (full target) Thesis: Solaris Energy Infrastructure raised Q3, Q4, AND issued an initial Q1 2027 EBITDA guide — that’s a triple-beat on guidance visibility, which is rare and highly valued in energy infrastructure. The “stronger core power services + acquired business contributions” narrative is the right kind of beat: organic plus M&A synergies firing together. This is AI data center power demand flowing through to energy infrastructure in real time. SEI is up 23% on the week but only trading at $62.77 vs. its 6-month high of $82.88 — there’s still a 30%+ round trip to recover. Levels: Exit near 20-day high resistance at $65.97 for quick trim; Fib 38.2% resistance at $67.81 is next. Support at SMA-50 of $59.57 — that’s your stop.

IONQ (+8.5%) — $42.87 → $46.84 (20-day high resistance) Thesis: IonQ raised full-year 2026 revenue guidance following the SkyWater Technology acquisition close — this is a real fundamental catalyst, not sector sympathy. The Commerce Department taking equity stakes in quantum computing peers (Rigetti, D-Wave) creates a sector-wide tailwind implying government validation of quantum as critical infrastructure. IonQ is the highest-quality name in the space with actual hardware AND now manufacturing control via SkyWater. Note: RSI is 53.7 — not overbought — and it’s sitting right at the Fib 61.8% retracement of $43.96, which is a natural decision point. A clean hold above here opens the door to $46-49. Levels: Exit at 20-day high of $46.84; next target is Fib 50% of $49.33. Support at SMA-50 of $41.10.

ALAB (+9.75%) — $310.40 → $336.81 (+8.5% upside) Thesis: Astera Labs is rallying as the AI connectivity trade broadens beyond NVIDIA into “picks and shovels” — Scorpio, Aries, and Taurus product lines are seeing strong demand as hyperscalers scale out AI clusters. The S&P 500 inclusion speculation (which ultimately didn’t pan out Friday) may resurface at the next rebalance. However, I want to flag a caution here: ALAB is trading at a 46.7x forward P/E vs. peer median of 18.4x — even on 104.5% revenue growth, that’s a 0.45 PEG which is cheap in isolation, but the stock is still 38% off its 6-month high of $483. This feels like a relief rally off an oversold base, not a new breakout. Levels: Exit at SMA-50 of $328.62 or Fib 38.2% retracement at $336.81. Critical support at Fib 50% of $291.64 — that’s your stop reference.

IREN (+7.3%) — $44.68 → $46.78 (20-day high) → $48.57 (Fib 50%) Thesis: IREN’s 2GW Sweetwater Hub getting conditional ERCOT “Base Load” status is a massive long-term capacity unlock — ERCOT conditional approval is the first bureaucratic gate before real power contracting begins at scale. With AI cloud revenue up 687% YoY, IREN is successfully pivoting its narrative from Bitcoin miner to AI infrastructure play, and the market is re-rating it accordingly. A top Wall Street analyst has a “double from here” price target. The RSI is a startling 6.18 — technically this stock has been deeply oversold for weeks, so this bounce has room. It’s up 26% on the week but still well off the 6-month high of $67.84. Levels: Exit at 20-day high of $46.78 or Fib 50% extension of $48.57. Support at Fib 61.8% of $44.03 is critical — a close below there is a warning sign.

BLTE (+13.2%) — $193.61 → $209.57 (+8.2% upside) Thesis: FDA Priority Review acceptance with a February 12, 2027 PDUFA date for tinlarebant in Stargardt Disease is a meaningful de-risking event — Priority Review means a 6-month review window and implies the FDA sees unmet need. At the stock’s Commercial Day, management was clearly setting up the commercial narrative. One caution: BLTE is at a 431% 3-year return and one analyst already flagged it looks “fully valued” at 99.8x forward P/E vs. peer median of 15.1x — that is objectively EXPENSIVE. The PDUFA binary is ~5 months out, and the valuation already prices optimism. This is a hold for existing longs, not a new entry. Levels: Exit at Fib 1.272 extension of $209.57. Support at Fib 23.6% of $179.76; SMA-50 at $159.10 is the real floor.

SNDK (+11.9%) — $1,740 → $1,919 (Fib 23.6% resistance) Thesis: Goldman spotting a “breakout signal” in SanDisk alongside Micron is a high-quality institutional catalyst — Goldman’s technical team flagging this pattern tends to attract quant and systematic buyers. Memory stocks are benefiting from the AI memory supercycle narrative (HBM demand from NVIDIA/AMD ecosystems). SNDK is +17% on the week but sits between SMA-50 ($1,543) as a solid floor and the 6-month high of $2,335 as the ceiling — there’s meaningful room above. Volume is light (0.13x average), which tempers conviction somewhat, but the Goldman seal of approval brings fresh eyeballs. Levels: Exit at Fib 23.6% retracement of $1,919. SMA-50 at $1,543 is the real support floor.

Headlines to Watch

Goldman Spots Breakout Signal for Micron, SanDisk Stocks — A Goldman technical endorsement on memory names could trigger systematic buying flows in MU and SNDK today; worth watching for follow-through into the afternoon session.
Quantum Stocks Rally as Commerce Department Takes Equity Stakes — Government equity participation in Rigetti and D-Wave is a structural signal for the quantum sector; the fine print on government ownership terms matters — this could be dilutive or restrictive, so read before chasing.
Bloom Energy Joins S&P 500 as The Trade Desk Leaves — Index inclusion forces passive fund buying in BE; this is a mechanical tailwind with a hard deadline on the rebalance date (~Sept. 21), making BE actionable with a time-limited catalyst.
Palantir Names Nebius as Preferred Sovereign AI Infrastructure Partner — NBIS gets a powerful endorsement from PLTR’s ecosystem, validating its neocloud positioning; Palantir partnerships tend to have real revenue follow-through, not just press release pop.
IBB Beat S&P 500 by 22 Points in Three Months — Are You Late? — Today’s PHVS and ROIV Phase 2/3 catalysts suggest biotech’s run has MORE legs; the question isn’t if you’re late — it’s whether you have quality names vs. speculative lottery tickets.
Rising Oil Prices + Canadian Retaliatory Tariffs — Dual macro headwinds create a ceiling on the broader market; energy stocks (XLE up pre-bell) could rotate into favor, but consumer discretionary and import-heavy names face margin compression risk.
Oracle Rallies 5% on Morgan Stanley Price Target Raise — AI cloud infrastructure re-rating continues; this validates the hyperscaler capex cycle is intact and is broadly bullish for the AI picks-and-shovels trade (ALAB, CBRS, NBIS adjacency).

Claude’s Top Picks

PHVS (+21.1% today, +23.3% week) — $42.67 → $46.29 (+8.5% upside) Valuation: Pre-revenue biotech with negative P/E, peers at 15.1x — standard for clinical-stage HAE names; valuation only becomes relevant post-NDA filing. Upside: 83% attack rate reduction is a blockbuster-level number in HAE — this is the kind of data that gets you to NDA filing and a partnering call from Big Pharma; the next 12 months are a value-creation runway. Risk: No SMA-200 available (newer name), and vol ratio is 1.58x — conviction buying is present but if broader biotech sentiment reverses on macro, pre-revenue names get hit hardest.

ROIV (+11.2% today, +12.1% week) — $38.83 → $43.31 (+11.5% upside) Valuation: Negative P/E (pre-profit) but Lisraya’s $35K/month pricing establishes real commercial revenue; the pipeline is being valued at a discount given the multi-program structure. Upside: Mosliciguat PH-ILD data is Phase 2 success — the path to Phase 3 initiation and eventual NDA is now derisked; Roivant’s “vant” structure allows fast-tracking development separately, which the market historically re-rates higher. Risk: Phase 2 to Phase 3 translation risk is real in pulmonary hypertension; if the Phase 3 design gets scrutinized by FDA, enthusiasm fades quickly; revenue decline of -33.5% YoY is a red flag to monitor.

IONQ (+8.5% today, +9.0% week) — $42.87 → $49.33 (+15.1% upside) Valuation: No forward P/E comp available for quantum pure-plays; use revenue growth trajectory as primary metric — SkyWater acquisition meaningfully expands near-term revenue recognition. Upside: Guidance raise + SkyWater close + Commerce Department sector validation in one day creates a multi-layer catalyst stack; RSI of 53.7 means you’re buying a reset, not a top. Risk: Quantum computing remains pre-commercial at scale; any disappointment at today’s Investor Day could reverse the move; SkyWater integration risk is real — manufacturing is hard.

SEI (+14.1% today, +23.6% week) — $62.77 → $67.81 (+8.0% upside) Valuation: Energy infrastructure trading at $62.77 vs. 6-month high of $82.88 — still 24% below its own recent peak despite improving fundamentals. Upside: Triple-raised guidance (Q3 + Q4 + initial Q1 2027 view) on AI data center power demand is the most durable macro theme in infrastructure right now; pricing power is expanding as the data center buildout accelerates. Risk: Energy infrastructure names are rate-sensitive; if today’s rising oil translates to broader macro concern about inflation re-acceleration, rate expectations could shift and compress multiple.

IREN (+7.3% today, +26.0% week) — $44.68 → $48.57 (+8.7% upside) Valuation: No forward P/E given the business model transition from BTC mining to AI cloud; use EV/Revenue — at sub-$50 with 687% AI cloud revenue growth, the market is not fully pricing the transition. Upside: ERCOT conditional “Base Load” status for 2GW Sweetwater is a long-duration capacity unlock that changes the capacity ceiling story; RSI of 6.18 means technically this has been washed out — the bounce has oxygen. Risk: RSI at 6 is anomalous and warrants scrutiny — this could reflect data issues or thin trading; BTC price sensitivity remains a tail risk if crypto sentiment reverses; the vol ratio of 0.12x means conviction is low, which is the biggest near-term concern.

Avoid

BLTE — At 99.8x forward P/E vs. peer median of 15.1x (6.6x premium), this is one of the most expensive biotech names in the market; with the PDUFA binary 5 months away, you’re paying for perfection and the risk/reward is asymmetric to the downside.

CBRS — Trading at 168x forward P/E vs. peer median of 18.4x; yes, $25.4B backlog and 74.3% revenue growth are impressive, but the stock is already pricing in several years of perfect execution; at $210 vs. Fib 61.8% support of $222.97, it’s also technically vulnerable — below that level opens a retest of SMA-50 at $203.71.

TARS — Up 26.5% on the week and at a 6-month high with RSI neutral, but priced at 38.5x forward P/E on 69% revenue growth; the XDEMVY story is real, but the Alkeus acquisition (Stargardt) adds execution risk and cash burn while the stock is already stretched from SMA-50 at $66.50 — nearly 40% below current price — meaning there’s no nearby support to lean on.

WSB Sentiment Check

AGI — WSB says: MIXED (55% bullish) | 250 mentions, 820 upvotes Claude says: DISAGREE — With 250 mentions and mixed sentiment, this has the profile of a crowded debate, not a clean trade; AGI is sitting at the Fib 61.8% support of $36.70 which is a technically meaningful level, but with 45% of WSB bearish and the chart showing a 28% decline from its 6-month high of $51.06, this looks like a falling knife debate rather than a breakout setup — I’d want a clear catalyst before getting involved.

MU — WSB says: BULLISH (80% bullish) | 91 mentions Claude says: AGREE — MU is at a 6-month high of $1,019.94, up from a low of $321.75 — an extraordinary recovery — and the Goldman breakout call on memory stocks provides institutional tailwind alongside the AI HBM supercycle narrative; the Fib 23.6% support at $1,002.95 is literally right here, making this a solid risk/reward entry for the WSB bull case; the technicals and fundamentals align.

NVDA — WSB says: BULLISH (80% bullish) | 52 mentions Claude says: PARTIALLY AGREE — NVDA is trading at $231.82 vs. a 6-month high of $235.47 — it’s essentially at its near-term ceiling; the Fib 1.272 extension of $254.64 is the next real target but the stock needs a fresh catalyst to break through $235; with vol ratio of only 0.07x, there’s no conviction buying behind today’s WSB enthusiasm — this is a great long-term hold but a low-urgency entry today.

BE — WSB says: BULLISH (80% bullish) | 48 mentions, 156 upvotes Claude says: AGREE — This is the most mechanically justified WSB call today: Bloom Energy’s S&P 500 inclusion (announced after close Friday) means passive fund buying is MANDATORY before the September 21 rebalance; BE is at $272.76, well above SMA-50 at $226.89, with Fib 1.272 extension at $407.41 as the long-term bull target; this is one of the clearest time-bounded catalysts in the market right now.

SNDK — WSB says: BULLISH (80% bullish) | 45 mentions Claude says: AGREE — Goldman breakout signal + AI memory supercycle + Motley Fool “superior buy” framing on the same day creates a multi-source catalyst stack; SNDK at $1,740 is well above SMA-50 at $1,543 with Fib 23.6% resistance at $1,919 as the near-term target; the 80% WSB bulls are right but volume is thin (0.13x) — size accordingly and don’t YOLO calls.

Earnings Scorecard

DSGX — REPORTED | Stock: -4.1% | Analyst Target: $100.23 EPS of $2.01 but the market didn’t care — the reaction likely reflects guidance disappointment or margin pressure; at -4% with a $100 analyst target vs. implied lower current price, this looks like an overreaction worth watching for a dip entry if fundamentals are intact.

ADBE — REPORTED | Stock: -3.5% | Analyst Target: $276.58 EPS of $17.48 but Adobe fell 3.5% — almost certainly reflects AI disruption concerns in its creative suite and fears of pricing power erosion; the “new CEO” news adds transition uncertainty; at $276 analyst target vs. a declining stock, this is a buy-the-dip candidate IF you believe AI fears are overpriced, but the CEO transition is a real overhang.

SAIL — REPORTED | EPS: -$0.25 | Stock: -2.4% | Analyst Target: $20.06 SailPoint reported a loss and the stock declined modestly — the -$0.25 EPS likely came in near expectations given the small reaction; identity governance software is a quality sector but the loss-making profile limits multiple expansion; hold rather than buy the dip here.

TTAN — REPORTED | EPS: -$1.46 | Stock: -2.0% | Analyst Target: $111.07 ServiceTitan’s -$1.46 EPS reflects ongoing investment phase — the mild -2% reaction suggests the market already knew this was a growth-at-all-costs story; $111 analyst target vs. current price implies significant upside for patient holders; the muted reaction is actually a green flag — when bad news doesn’t kill it, the floor is strong.

CHWY — REPORTED | EPS: $0.60 | Stock: -0.9% | Analyst Target: $30.32 Chewy earned $0.60 with a -0.9% reaction — muted response to a profitable quarter suggests the market isn’t rewarding execution here, likely reflecting pet retail TAM concerns; not a buy-the-dip at current levels given tepid momentum.

M — REPORTED | EPS: $2.42 | Stock: +0.8% | Analyst Target: $23.23 Macy’s delivered $2.42 and barely moved +0.8% — the muted reaction despite a solid EPS print reflects structural department store skepticism; reaction is underdone if the number genuinely beat, but the terminal value debate caps upside; neutral.

ABM — REPORTED | EPS: $2.60 | Stock: -0.8% | Analyst Target: $52.43 ABM beat estimates and tightened full-year guidance but fell 0.8% — a classic “sell the news” on a quality but boring industrial services name; this is a hold, not a chase.

KR — REPORTED | EPS: $1.71 | Stock: -0.4% | Analyst Target: $70.27 Kroger’s modest decline after reporting is typical for defensive grocery names — market wants growth, not stability; $70.27 analyst target provides a valuation floor argument; hold for yield-seekers, no urgency for growth-focused traders.

AEO — REPORTED | EPS: $1.59 | Stock: +0.3% | Analyst Target: $19.70 American Eagle with a near-flat reaction on $1.59 EPS — the apparel sector is in a tough spot with tariff uncertainty and consumer spending pressure; muted move suggests the quarter was in-line; hold at best.

This brief is for informational purposes only and does not constitute investment advice. All price targets are technical reference points, not guarantees of future performance.